• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃H⁺,K⁺-ATP酶的钾离子竞争性抑制剂AZD0865的作用机制

Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.

作者信息

Gedda Karin, Briving Carin, Svensson Karin, Maxvall Ingela, Andersson Kjell

机构信息

AstraZeneca R&D, Mölndal S-431 83, Sweden.

出版信息

Biochem Pharmacol. 2007 Jan 15;73(2):198-205. doi: 10.1016/j.bcp.2006.09.020. Epub 2006 Sep 24.

DOI:10.1016/j.bcp.2006.09.020
PMID:17081503
Abstract

AZD0865 is a member of a drug class that inhibits gastric H(+),K(+)-ATPase by K(+)-competitive binding. The objective of these experiments was to characterize the mechanism of action, selectivity and inhibitory potency of AZD0865 in vitro. In porcine ion-leaky vesicles at pH 7.4, AZD0865 concentration-dependently inhibited K(+)-stimulated H(+),K(+)-ATPase activity (IC(50) 1.0+/-0.2 microM) but was more potent at pH 6.4 (IC(50) 0.13+/-0.01 microM). The IC(50) values for a permanent cation analogue, AR-H070091, were 11+/-1.2 microM at pH 7.4 and 16+/-1.8 microM at pH 6.4. These results suggest that the protonated form of AZD0865 inhibits H(+),K(+)-ATPase. In ion-tight vesicles, AZD0865 inhibited H(+),K(+)-ATPase more potently (IC(50) 6.9+/-0.4 nM) than in ion-leaky vesicles, suggesting a luminal site of action. AZD0865 inhibited acid formation in histamine- or dibutyryl-cAMP-stimulated rabbit gastric glands (IC(50) 0.28+/-0.01 and 0.26+/-0.003 microM, respectively). In ion-leaky vesicles at pH 7.4, AZD0865 (3 microM) immediately inhibited H(+),K(+)-ATPase activity by 88+/-1%. Immediately after a 10-fold dilution H(+),K(+)-ATPase inhibition was 41%, indicating reversible binding of AZD0865 to gastric H(+),K(+)-ATPase. In contrast to omeprazole, AZD0865 inhibited H(+),K(+)-ATPase activity in a K(+)-competitive manner (K(i) 46+/-3 nM). AZD0865 inhibited the process of cation occlusion concentration-dependently (IC(50) 1.7+/-0.06 microM). At 100 microM, AZD0865 reduced porcine renal Na(+),K(+)-ATPase activity by 9+/-2%, demonstrating a high selectivity for H(+),K(+)-ATPase. Thus, AZD0865 potently, K(+)-competitively, and selectively inhibits gastric H(+),K(+)-ATPase activity and acid formation in vitro, with a fast onset of effect.

摘要

AZD0865是一类通过钾离子竞争性结合来抑制胃H⁺,K⁺-ATP酶的药物成员。这些实验的目的是在体外表征AZD0865的作用机制、选择性和抑制效力。在pH 7.4的猪离子泄漏囊泡中,AZD0865浓度依赖性地抑制钾离子刺激的H⁺,K⁺-ATP酶活性(半数抑制浓度[IC₅₀]为1.0±0.2微摩尔/升),但在pH 6.4时更有效(IC₅₀为0.13±0.01微摩尔/升)。一种永久性阳离子类似物AR-H070091在pH 7.4时的IC₅₀值为11±1.2微摩尔/升,在pH 6.4时为16±1.8微摩尔/升。这些结果表明AZD0865的质子化形式抑制H⁺,K⁺-ATP酶。在离子紧密囊泡中,AZD0865比在离子泄漏囊泡中更有效地抑制H⁺,K⁺-ATP酶(IC₅₀为6.9±0.4纳摩尔/升),表明其作用位点在管腔。AZD0865抑制组胺或二丁酰环磷腺苷刺激的兔胃腺中的酸形成(IC₅₀分别为0.28±0.01和0.26±

相似文献

1
Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase.胃H⁺,K⁺-ATP酶的钾离子竞争性抑制剂AZD0865的作用机制
Biochem Pharmacol. 2007 Jan 15;73(2):198-205. doi: 10.1016/j.bcp.2006.09.020. Epub 2006 Sep 24.
2
Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.钾离子竞争性H⁺,K⁺ -ATP酶抑制剂AZD0865在分离的大鼠胃腺中的特性
Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G838-43. doi: 10.1152/ajpgi.00120.2006. Epub 2006 Jun 22.
3
Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole.T-330(2-[(2-二甲基氨基苄基)亚磺酰基]-1-(3-甲基吡啶-2-基)咪唑)对大鼠胃H⁺/K⁺-ATP酶的可逆性抑制作用
J Pharmacol Exp Ther. 1996 Apr;277(1):28-33.
4
Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.3-氨基-5-甲基-2-(2-甲基-3-噻吩基)咪唑并[1,2-a]噻吩并[3,2-c]吡啶(SPI-447)对胃H⁺,K⁺-ATP酶的抑制作用
Jpn J Pharmacol. 1997 Nov;75(3):303-6.
5
Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
Bioorg Med Chem Lett. 2007 Oct 1;17(19):5374-8. doi: 10.1016/j.bmcl.2007.08.003. Epub 2007 Aug 11.
6
Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews.从毛喉鞘蕊花中分离得到的二萜类化合物——普列克亭酮A对胃H⁺,K⁺ -ATP酶的抑制作用
J Ethnopharmacol. 2007 Apr 20;111(1):1-7. doi: 10.1016/j.jep.2006.09.046. Epub 2006 Nov 11.
7
Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.替那拉唑对胃H⁺,K⁺ -ATP酶体外和体内抑制活性的表征。
Biochem Pharmacol. 2006 Mar 14;71(6):837-49. doi: 10.1016/j.bcp.2005.11.030. Epub 2006 Jan 10.
8
Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.吡咯嗪衍生物ML 3000对胃H,K - ATP酶活性及胃上皮细胞白细胞介素- 8分泌的抑制作用
BMC Gastroenterol. 2004 Feb 10;4:4. doi: 10.1186/1471-230X-4-4.
9
Inhibition of P-type ATPases by [(dihydroindenyl)oxy]acetic acid (DIOA), a K+ -Cl- cotransporter inhibitor.[(二氢茚基)氧基]乙酸(DIOA,一种钾离子-氯离子共转运体抑制剂)对P型ATP酶的抑制作用
Eur J Pharmacol. 2007 Apr 10;560(2-3):123-6. doi: 10.1016/j.ejphar.2006.12.031. Epub 2007 Jan 19.
10
The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands.钙敏感受体作为新鲜分离的人胃腺中胃酸分泌的调节剂。
Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1084-90. doi: 10.1152/ajpgi.00571.2004. Epub 2005 Aug 18.

引用本文的文献

1
Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB).替戈拉赞:一种新型、高选择性且强效的钾离子竞争性酸阻滞剂(P-CAB)。
Eur J Clin Pharmacol. 2025 May 29. doi: 10.1007/s00228-025-03850-6.
2
A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis.一项关于钾离子竞争性酸阻滞剂(X842)与兰索拉唑治疗糜烂性食管炎患者的随机对照试验。
Clin Transl Gastroenterol. 2025 Apr 1;16(4):e00803. doi: 10.14309/ctg.0000000000000803.
3
How ligands modulate the gastric H,K-ATPase activity and its inhibition by tegoprazan.
配体如何调节胃H⁺,K⁺-ATP酶活性以及替戈拉赞对其的抑制作用。
J Biol Chem. 2024 Dec;300(12):107986. doi: 10.1016/j.jbc.2024.107986. Epub 2024 Nov 14.
4
Potassium-competitive acid blockers and gastroesophageal reflux disease.钾离子竞争型酸阻断剂与胃食管反流病。
World J Gastroenterol. 2022 Jul 28;28(28):3608-3619. doi: 10.3748/wjg.v28.i28.3608.
5
The role of vonoprazan in patients with erosive esophagitis.沃克帕唑在糜烂性食管炎患者中的作用。
Therap Adv Gastroenterol. 2022 Sep 13;15:17562848221122623. doi: 10.1177/17562848221122623. eCollection 2022.
6
The Physiology of the Gastric Parietal Cell.胃壁细胞的生理学。
Physiol Rev. 2020 Apr 1;100(2):573-602. doi: 10.1152/physrev.00016.2019. Epub 2019 Oct 31.
7
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.富马酸沃克索拉唑,一种新型钾离子竞争性酸阻滞剂,用于治疗胃食管反流病:迄今为止的安全性和临床证据。
Therap Adv Gastroenterol. 2018 Jan 9;11:1756283X17745776. doi: 10.1177/1756283X17745776. eCollection 2018.
8
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.胃食管反流病药物治疗的最新进展
Dig Dis Sci. 2017 Dec;62(12):3298-3316. doi: 10.1007/s10620-017-4830-5. Epub 2017 Nov 6.
9
Protonated form: the potent form of potassium-competitive acid blockers.质子化形式:钾竞争性酸阻滞剂的有效形式。
PLoS One. 2014 May 20;9(5):e97688. doi: 10.1371/journal.pone.0097688. eCollection 2014.
10
Current pharmacological management of gastroesophageal reflux disease.胃食管反流病的当前药物治疗管理。
Gastroenterol Res Pract. 2013;2013:983653. doi: 10.1155/2013/983653. Epub 2013 Jun 26.